Juan Gonzalez-Valdivieso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Gonzalez-Valdivieso has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Girotti
Smart Devices for NanoMedicine, University of Valladolid, LUCIA Building, 47011 Valladolid, Spain
9 shared publications - Irene M. Min
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
9 shared publications - Moonsoo M. Jin
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
9 shared publications - Aidan C. Burnett
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
8 shared publications - Bing He
Weill Cornell Medicine 5 Department of Pathology and Laboratory Medicine New York, New York
8 shared publications - Dessislava Stefanova
Weill Cornell Medicine 3 Department of Surgery New York, New York
8 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Research Square
Specific laminin binding to interleukins enhances diabetic wound healing
Laminin (LN), a major component of the extracellular matrix (ECM), modulates tissue morphogenesis and is known to act as a reservoir for growth factors (GFs). Here we show, for the first time, that laminins and fibronectin also bind interleukins (ILs), through sites and binding behaviours distinct from those governing GF binding and independent of heparin. This finding extends the reservoir function of the ECM beyond growth factor biology and opens a matrix-biology perspective on immune regulation. We further show that LN111 potentiates IL-10 signalling during M2c macrophage polarization via crosstalk with the integrin α6 (ITGA6) axis. As a translational application, a PEG-maleimide (PEG-MAL) hydrogel functionalized with LN111 for IL-10 delivery significantly improves wound healing in a murine model of type 2 diabetes. During this work, we found that IL-binding sites sterically interfere with commercial antibodies. To address this, we developed a high-throughput approach that replaces immunolabelling with chemical labelling and combines AI-assisted docking with wet-lab validation to screen binding sites within large ECM proteins.
- 8 October 2026
- Published by Springer Nature in Research Square
Open AccessSpecific laminin binding to interleukins enhances diabetic wound healing
Laminin (LN), a major component of the extracellular matrix (ECM), modulates tissue morphogenesis and is known to act as a reservoir for growth factors (GFs). Here we show, for the first time, that laminins and fibronectin also bind interleukins (ILs), through sites and binding behaviours distinct from those governing GF binding and independent of heparin. This finding extends the reservoir function of the ECM beyond growth factor biology and opens a matrix-biology perspective on immune regulation. We further show that LN111 potentiates IL-10 signalling during M2c macrophage polarization via crosstalk with the integrin α6 (ITGA6) axis. As a translational application, a PEG-maleimide (PEG-MAL) hydrogel functionalized with LN111 for IL-10 delivery significantly improves wound healing in a murine model of type 2 diabetes. During this work, we found that IL-binding sites sterically interfere with commercial antibodies. To address this, we developed a high-throughput approach that replaces immunolabelling with chemical labelling and combines AI-assisted docking with wet-lab validation to screen binding sites within large ECM proteins.
- Open Access
- 7 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 831
Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective
Over the past decade, the use of nanomaterials and nanomedical devices has been increasingly explored for cancer treatment. Although the outcomes of conventional therapies have improved patient survival, these approaches still present important limitations for some types of cancer and metastasis. Challenges such as poor drug accumulation in solid tumors and lack of specificity and selectivity can be addressed through alternative nanomedicine-based treatments. Among the wide range of nanoplatforms whose composition and shape have been designed for cancer treatment, this review focuses specifically on those based on natural proteins, including advanced carriers and engineered proteins bearing active targeting and/or therapeutic agents. The objective of this review is to provide a comparative and translational analysis of protein-based nanomaterials for cancer therapy, highlighting their unique characteristics, such as biocompatibility, biodegradability, and the ability to integrate bioactive peptides that can trigger or respond to tumor-specific or altered physiological stimuli. Several protein-based nanomedical devices have been developed for theranostic applications, demonstrating enhanced performance in tumor imaging and cancer treatment. This review introduces a structured analytical framework that classifies protein-based nanomaterials according to their biological origin, functional design, and clinical readiness, enabling systematic evaluation across platforms. Rather than providing a descriptive overview, this work offers a structured comparative analysis of protein-based nanomaterials, highlighting design trade-offs, translational challenges, and factors influencing clinical applicability.
- 7 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 831
Open AccessProtein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective
Over the past decade, the use of nanomaterials and nanomedical devices has been increasingly explored for cancer treatment. Although the outcomes of conventional therapies have improved patient survival, these approaches still present important limitations for some types of cancer and metastasis. Challenges such as poor drug accumulation in solid tumors and lack of specificity and selectivity can be addressed through alternative nanomedicine-based treatments. Among the wide range of nanoplatforms whose composition and shape have been designed for cancer treatment, this review focuses specifically on those based on natural proteins, including advanced carriers and engineered proteins bearing active targeting and/or therapeutic agents. The objective of this review is to provide a comparative and translational analysis of protein-based nanomaterials for cancer therapy, highlighting their unique characteristics, such as biocompatibility, biodegradability, and the ability to integrate bioactive peptides that can trigger or respond to tumor-specific or altered physiological stimuli. Several protein-based nanomedical devices have been developed for theranostic applications, demonstrating enhanced performance in tumor imaging and cancer treatment. This review introduces a structured analytical framework that classifies protein-based nanomaterials according to their biological origin, functional design, and clinical readiness, enabling systematic evaluation across platforms. Rather than providing a descriptive overview, this work offers a structured comparative analysis of protein-based nanomaterials, highlighting design trade-offs, translational challenges, and factors influencing clinical applicability.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
HLA dependence of engineered T-cell populations quantified as Δ target viability
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
HLA dependence of engineered T-cell populations quantified as Δ target viability
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypic analysis of engineered T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypic analysis of engineered T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypes of RM-ATC and donor-matched primary T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypes of RM-ATC and donor-matched primary T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Increased NFAT activity mounted by TCR-8505C/ICCR expression
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Increased NFAT activity mounted by TCR-8505C/ICCR expression
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Generation of 8505C-OKT3 cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Generation of 8505C-OKT3 cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
TCRa depletion in ICCR-T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
TCRa depletion in ICCR-T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Conjugate analysis of engineered T cells and IFNγ-prestimulated A375-MA2 cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Conjugate analysis of engineered T cells and IFNγ-prestimulated A375-MA2 cells
- 8 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , OF1-OF17
An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-Cell Function
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.
- 8 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , OF1-OF17
An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-Cell Function
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.